Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00874848
Other study ID # BT-CL-PGG-LCA0822
Secondary ID
Status Completed
Phase Phase 2
First received April 1, 2009
Last updated March 3, 2014
Start date August 2009
Est. completion date September 2013

Study information

Verified date March 2014
Source Biothera
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date September 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Ethics Committee (IRB/EC)

2. Is between the ages of 18 and 75 years old, inclusive

3. Has histologically or cytologically confirmed stage IIIB (malignant pericardial or pleural effusion) or stage IV non-small cell lung cancer

4. Has measurable disease, defined as at least one tumor that fulfills the criteria for a target lesion according to RECIST

5. Has an ECOG performance status of 0 or 1

6. Has a life expectancy of > 3 months

7. Has adequate hematologic function as evidenced by:

- ANC = 1,500/µL

- PLT = 100,000/µL

- HGB = 9 g/dL obtained within 1 week prior to the first dose of study medication;

8. Has adequate renal function as evidenced by:

- Serum creatinine = 1.5 X the upper limit of normal (ULN) for the reference lab

- Urine dipstick for proteinuria of < 1+ (i.e., either 0 or trace) within 2 weeks of Day 1 If urine dipstick is = 1+, then urine protein excretion must be = 500 mg over a 24 hour collection obtained within 1 week prior to the first dose of study medication;

9. Has adequate hepatic function as evidenced by:

- Serum total bilirubin = 1.0 mg/dL

- AST = 2.5X ULN for the reference lab (= 5X ULN for subjects with known hepatic metastases)

- ALT = 2.5X ULN for the reference lab (= 5X ULN for subjects with known hepatic metastases) obtained within 1 week prior to the first dose of study medication;

10. If a woman of childbearing potential or a fertile man (and his partners), must agree to use an effective form of contraception (hormonal contraceptive, double-barrier method or abstinence) during the study.

Exclusion Criteria:

1. Has received prior systemic chemotherapy at any time for lung cancer;

2. Has received previous radiation therapy to >30% of active bone marrow or any radiation therapy within 3 weeks of Day 1

3. Has a known hypersensitivity to baker's yeast, or has an active yeast infection

4. Has had previous exposure to Betafectin® or Imprime PGG

5. Has an active infection

6. Presents with any of the following medical diagnoses/conditions at the time of screening:

- Central nervous system (CNS) metastases

- Peripheral neuropathy = grade 2 from any cause

- Fever of >38.5° C within 3 days prior to screening or Day 1, initial dosing

- Known HIV/AIDs, Hepatitis B, Hepatitis C, connective tissue or autoimmune disease, or other clinical diagnosis, ongoing or intercurrent illness that in the physician's opinion could interfere with participation

7. Has a history of any of the following medical diagnoses/conditions:

- Myocardial infarction or an unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure) within the previous 6 months

- Second malignancy within the previous 5 years, other than basal cell carcinoma, cervical intra-epithelial neoplasia or curatively treated prostate cancer with a PSA of <2.0 ng/mL

8. Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab

9. Has a know sensitivity to Cremophor EL

10. Has previously received treatment with cetuximab

11. If female, is pregnant or breast-feeding

12. Is receiving concurrent investigational therapy or has received investigational therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication)

13. Has previously received an organ or progenitor/stem cell transplant.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Imprime PGG® Injection
4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
Cetuximab
initial loading dose of 400 mg/m2 over 120 min and subsequent doses at 250 mg/m2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
Drug:
Paclitaxel
200 mg/m2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Carboplatin
dose equal to an AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

Locations

Country Name City State
Germany Helios Clinic Emil von Behring Berlin
Germany Municipal Clinic Frankfurt Hoescht Frankfurt
Germany Georg-August University Gottingen Gottingen
Germany University Clinical Heidelberg Heidelberg
Germany Clinic Minden Minden
Germany Techincal University of Munich Munich
Germany Clinic Nurnberg Nord Nuremberg
Germany Universitätsklinikum Ulm Ulm
Germany HELIOS Klinikum Wuppertal, Medizinische Klinik 1 Wuppertal
United States Medical College of Georgia Augusta Georgia
United States Mary Crowley Medical Research Center Dallas Texas
United States Allison Cancer Center Midland Texas
United States University of Minnesota Minneapolis Minnesota
United States Providence Medical Group Terre Haute Indiana

Sponsors (1)

Lead Sponsor Collaborator
Biothera

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the objective response rate (ORR) in each study arm Approximately 1.5 years No
Secondary To determine the disease control rate (DCR) in each study arm Approximately 1.5 years No
Secondary To determine the complete response (CR), partial response (PR), and stable disease (SD) rates in each study arm Approximately 1.5 years No
Secondary To determine the duration of objective tumor response in each study arm Approximately 1.5 years No
Secondary To determine the duration of stable disease in each study arm Approximately 1.5 years No
Secondary To determine the duration of time to progression (TTP) in each study arm Approximately 1.5 years No
Secondary To assess the safety of the dosing regimen in each study arm Approximately 1.5 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2